Analysis of Prognostic and Survival Factors Related to Treatment of Low-Grade Astrocytomas in Adults

Prognostic factors for low-grade astrocytomas have been proposed, but optimal treatment remains controversial. Eighty-eight consecutive adult patients with supratentorial low-grade astrocytomas were retrospectively reviewed to determine specific factors influencing outcome. All underwent craniotomy (43 radical resections, 45 nonradical resections). Sex, age at diagnosis, preoperative Karnofsky performance status (KPS), tumor location, estimated extent of resection, radiation, chemotherapy, histological type, p53 status, MIB-1 staining and the apoptotic index were assessed as parameters for prognostic significance. KPS (p = 0.03), tumor location (p < 0.001), extent of surgical resection (p < 0.001) and radiotherapy (p = 0.01) were significantly assoicated with longer survival rates by univariate analysis. Multivariate analysis also showed a significant correlation between radiation therapy after surgical removal and survival time (p < 0.001). p53 status was not of importance in determining the necessity for radiotherapy. Radical surgical removal is the most important factor in the management of low-grade astrocytomas. Radiation therapy appears to be effective in improving the prognosis regardless of the extent of surgical resection or the p53 status.

[1]  D. Louis,et al.  Use of MIB‐1 (Ki‐67) Immunoreactivity in Differentiating Grade II and Grade III Gliomas , 1996, Journal of neuropathology and experimental neurology.

[2]  W. Shapiro.  Treatment of neuroectodermal brain tumors , 1982, Annals of neurology.

[3]  P. Workman.  To pop or not to pop: p53 as a critical modulator of tumour responsiveness to therapy in vivo? , 1995, Human & experimental toxicology.

[4]  Mitsutoshi Nakamura,et al.  p53‐independent WAF1 induction by ACNU in human glioblastoma cells , 1996, Molecular carcinogenesis.

[5]  K. Skullerud,et al.  Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Piantadosi,et al.  Low‐grade cerebral astrocytomas: Survival and quality of life after radiation therapy , 1990, Cancer.

[7]  Y. Shibamoto,et al.  Supratentorial low‐grade astrocytoma. Correlation of computed tomography findings with effect of radiation therapy and prognostic variables , 1993, Cancer.

[8]  C. Daumas-Duport,et al.  Radiation therapy in the management of low-grade supratentorial astrocytomas. , 1989, Journal of neurosurgery.

[9]  J. Bruner,et al.  Correlation of p53 immunoreactivity and sequencing in patients with glioma , 1996, Molecular carcinogenesis.

[10]  C. Compton,et al.  Proliferating cell nuclear antigen and mitotic activity in rectal cancer: predictor of response to preoperative irradiation. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Thompson,et al.  Apoptosis in the pathogenesis and treatment of disease , 1995, Science.

[12]  S. Ben‐Sasson,et al.  Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation , 1992, The Journal of cell biology.

[13]  D. Brachman,et al.  p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. , 1993, Cancer research.

[14]  R. Miralbell,et al.  Radiotherapy for supratentorial low-grade gliomas: results and prognostic factors with special focus on tumour volume parameters. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  B. Scheithauer,et al.  Supratentorial pilocytic astrocytomas. A clinicopathologic, prognostic, and flow cytometric study of 51 patients , 1993, Cancer.

[16]  J. Delattre,et al.  A prospective study of cognitive functions following conventional radiotherapy for supratentorial gliomas in young adults: 4-year results. , 1996, International journal of radiation oncology, biology, physics.

[17]  Douglas C. Miller,et al.  Treatment and survival of low-grade astrocytoma in adults--1977-1988. , 1992, Neurosurgery.

[18]  H. Thaler,et al.  Morbidity and mortality of craniotomy for excision of supratentorial gliomas , 1988, Neurology.

[19]  D. Housman,et al.  p53 status and the efficacy of cancer therapy in vivo. , 1994, Science.

[20]  S. Tsunoda,et al.  Immunohistochemical detection of CDKN2, retinoblastoma and p53 gene products in primary astrocytic tumors. , 1996, International journal of oncology.

[21]  M. Mikhael,et al.  Supratentorial gliomas: surgical considerations and immediate postoperative results. Gross total resection versus partial resection. , 1987, Neurosurgery.

[22]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[23]  B. Fisher,et al.  Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Faist,et al.  Supratentorial World Health Organization Grade 2 astrocytomas and oligoastrocytomas , 1997, Cancer.

[25]  S. Lowe,et al.  p53-Dependent apoptosis suppresses tumor growth and progression in vivo , 1994, Cell.

[26]  T. Mikkelsen,et al.  Clonal expansion of p53 mutant cells is associated with brain tumour progression , 1992, Nature.

[27]  A. Chiò,et al.  Prognostic factors in well-differentiated cerebral astrocytomas in the adult. , 1989, Neurosurgery.

[28]  B. Scheithauer,et al.  Histological Typing of Tumours of the Central Nervous System , 1993, World Health Organization.

[29]  S. Tsunoda,et al.  Retinoblastoma protein expression and MIB‐1 correlate with survival of patients with malignant astrocytoma , 1997, Cancer.

[30]  R. Makuch,et al.  Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. , 1996, Neurosurgery.

[31]  G. Demers,et al.  Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. , 1996, Cancer research.

[32]  K. Fulling,et al.  The value of radiation therapy in addition to surgery for astrocytomas of the adult cerebrum , 1985, Cancer.

[33]  Johannes Gerdes,et al.  Monoclonal antibodies against recombinant parts of the Ki‐67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave‐processed formalin‐fixed paraffin sections , 1992, The Journal of pathology.

[34]  P. Warnke,et al.  Low grade supratentorial astrocytomas: Management and prognostic factors , 1994, Cancer.

[35]  J. M. Lee,et al.  p53 mutations increase resistance to ionizing radiation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[36]  S. Tsunoda,et al.  Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas , 1996, Cancer.

[37]  D. Kondziolka,et al.  Survival after stereotactic biopsy and irradiation of cerebral nonanaplastic, nonpilocytic astrocytoma. , 1995, Journal of neurosurgery.

[38]  B. Scheithauer,et al.  Histological Classification of Tumours of the Central Nervous System , 1993 .

[39]  M. Prados,et al.  Gemistocytic astrocytomas: a reappraisal. , 1991, Journal of neurosurgery.